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Retrospective molecular genetic analysis of 166 My-
cobacterium intracellulare isolates showed that 143 (86%) 
strains could be assigned to Mycobacterium chimaera sp. 
nov. Of 97 patients from whom M. chimaera sp. nov. was 
isolated, only 3.3% exhibited mycobacterial lung disease, 
whereas all M. intracellulare isolates caused severe pulmo-
nary infections.
B
acteria of the Mycobacterium avium complex (MAC) 
play an important role among infections caused by 
nontuberculous mycobacteria (NTM). MAC consists of 
the 2 well-established species, M. avium (which has 4 
subspecies) and M. intracellulare, as well as several other 
closely related mycobacteria (1). Recently, a new species 
derived from the group of unnamed members of the MAC 
has been deﬁ  ned. It combines features characteristic of dif-
ferent MAC members and has been named M. chimaera 
sp. nov. (2).
Based on the sequence of the 16–23S internal tran-
scribed spacer (ITS) region, this species genetically cor-
responds to sequevar MAC-A and differs from M. intra-
cellulare type strain, sequevar MIN-A (DSMZ 43223) by 
20 nt mismatches (2,3). In contrast, the 16S rRNA gene 
sequence is identical, except for 1 nt mismatch, with that of 
the M. intracellulare type strain. Because sequencing of the 
16S rDNA still is considered the approved standard for the 
identiﬁ  cation of NTMs, M. chimaera sp. nov. usually has 
been misreported as M. intracellulare. Molecular genetic 
standard tools in clinical microbiologic laboratories do not 
differentiate MAC members. These tools merely provide 
a rough classiﬁ  cation in M. intracellulare and M. avium 
and/or the MAC group as a whole. Currently, a detailed 
genotyping of MAC is restricted to research laboratories. 
Nevertheless, several studies have shown that certain sero-
types or genotypes were associated with different clinical 
manifestations of MAC infection concerning the patient 
groups affected, the localization and course of disease, and 
the antimicrobial drug resistance patterns (4,5).
The Study
Since available data on the epidemiology of M. chi-
maera sp. nov. are sparse, we performed a retrospective 
study to determine the frequency of its occurrence within 
the group of MAC-positive clinical specimens and its 
possible role in causing human disease in comparison to 
M. intracellulare. We reanalyzed mycobacterial isolates 
from 97 in-house patients of the Charité University Hos-
pital that have been processed in our laboratory from 2002 
through 2006. An additional 69 isolates were provided by 
the National Reference Center (NRC) for Mycobacteria 
in Borstel, Germany. All strains had previously been clas-
siﬁ  ed as M. intracellulare by 16S rDNA–based methods. 
In addition to the partial 16S rRNA gene, we sequenced 
the 16S–23S ITS region to allow for unambiguous identi-
ﬁ  cation. Ampliﬁ  cation of the partial 16S rRNA gene was 
performed according to a standard procedure (6). For the 
ampliﬁ  cation of the ITS, the following primers were used: 
Sp1 (5′-ACC TCC TTT CTA AGG AGC ACC-3′) and 
Mb23S.44n (5′-TCT CGA TGC CAA GGC ATC CAC 
C-3′) (7,8). PCR conditions and the sequencing procedure 
are described elsewere (9). The assignment to sequevars 
was based on the ITS sequence, according to the taxon-
omy introduced by Frothingham and Wilson (3). Labo-
ratory analysis was performed without knowledge of the 
clinical course of the disease. The frequency distribution 
of the 166 strains according to their species or sequevar 
designations is presented in Table 1.
In addition, we tested the application of denaturating 
high-performance liquid chromatography (DHPLC) for the 
identiﬁ  cation of the ITS PCR product to distinguish M. in-
tracellulare, type strain, and M. chimaera sp. nov. DHPLC 
is a semiautomated, quick, and sensitive technique and has 
been used for the detection of genetic variations predomi-
nantly for genotyping purposes of a wide range of human 
diseases (10). Recently, it has also been introduced for 
the identiﬁ  cation and genotyping of bacterial species (11) 
and yeasts (12). The ampliﬁ  ed ITS gene fragments were 
separated on the WAVE 3500 HT System (Transgenom-
ic, Omaha, NE, USA). Optimal separation was achieved 
at an oven temperature of 61.5°C and a ﬂ  ow rate of 1.4 
mL/min on an integrated DNASep HT cartridge. Samples 
were loaded in 53.5% buffer A (0.1 mmol/L triethylam-
moniumacetate [TEAA]) and 46.5% buffer B (0.1 mmol/L 
TEAA in 25% acetonitrile). After 30 s, buffer B was set 
to 51.5%, reaching 60.5% after an additional 4.5 min. The 
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next injection. Analysis was accomplished with Navigator 
software version 1.5.4 (Transgenomic).
Both reference strains, M. intracellulare, sequevar 
Min-A (DSMZ 43223), and M. chimaera sp. nov., seque-
var MAC-A (DSMZ 44623), showed reproducible peak 
proﬁ  les. M. avium spp. avium, sequevar Mav-A, DSMZ 
44156 (21 mismatches to M. intracellulare, sequevar 
Min-A; 18 mismatches to M. chimaera sp. nov.,) and M. 
intracellulare, sequevar Min-C (2 mismatches to M. intra-
cellulare, sequevar Min-A; 14 mismatches to M. chimaera 
sp. nov.) served as negative run controls providing a differ-
ent peak location. All clinical M. intracellulare, sequevar 
Min-A strains, and M. chimaera sp. nov. strains (sequevar 
MAC-A) could be allocated unequivocally to the 2 refer-
ence strains by their congruent peak patterns (Figure). M. 
avium complex isolates, sequevars MAC-C and MAC-E, 
and  M. intracellulare isolates, sequevar Min-C, showed 
different peak proﬁ  les that could easily be separated from 
the 2 reference species. All DHPLC results could be repro-
duced in a second run conducted on another day.
The clinical relevance of M. intracellulare/chimaera 
sp. nov. strains isolated from respiratory specimens of 97 
in-house patients of the Charité University Hospital has 
been assessed according to the 1997 American Thoracic 
Society criteria for NTB lung disease (13). The data have 
been drawn from past hospital records. Cases were subdi-
vided into 3 categories: clinically relevant, clinically not 
relevant, and undetermined (Table 2). A clinical follow up 
of the 69 isolates provided by the NRC for mycobacteria 
was not possible. The characteristics of the patients with 
mycobacterial infection resemble already known features, 
such as underlying lung disease, immunosuppression, fe-
male sex, and microscopically positive respiratory samples 
(online Appendix Table, available from www.cdc.gov/
EID/content/14/9/1443-appT.htm). 
Conclusions
DHPLC was a rapid and reliable method for distin-
guishing M. intracellulare type strain from M. chimaera sp. 
nov. within a well-deﬁ  ned group of mycobacterial isolates. 
Low costs and the high degree of automation predispose 
this technique for epidemiologic studies. Our results show 
that M. chimaera sp. nov. accounts for most of the myco-
bacterial isolates formerly classiﬁ  ed as M. intracellulare. 
The small number of clinically relevant isolates (3.3%) 
suggests relatively low pathogenicity. As most other stud-
ies assessing the pathogenic potential of clinical NTM iso-
lates referred either to members of the whole MAC group 
(inclusively M. avium) or to the complete NTM spectrum, 
their results cannot be compared (14). Our observations are 
not concordant with those of Tortoli et al. (who suspected 
that M. chimaera sp. nov. was highly virulent), possibly 
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Table 1. Distribution of mycobacterial species and sequevars* 
Species, sequevar† 
Total isolates,
no. (%), n = 166 
Isolates from Charité,‡ 
no. (%), n = 97 
Isolates from NRC,‡ 
no. (%), n = 69  Odds ratio (p value§) 
MAC
  MAC-A  143 (86.1)  90 (92.8)  53 (76.8)  3.88 (p = 0.003) 
  MAC-C 2 (1.2)  1 (1.0)  1 (1.5)  ND
  MAC-E  1 (0.6)  1 (1.0)  0 ND
Min
  Min-A 17 (10.2)  3 (3.1)  14 (20.3)  0.12 (p<0.001) 
  Min-C  3 (1.8)  2 (2.1)  1 (1.5)  ND
*MAC, M. avium complex species; MAC-A, M. chimaera sp. nov.; ND, not done; Min, M. intracellulare; Min-A, M. intracellulare type strain. 
†Classification of MAC strains according to the taxonomy of Frothingham and Wilson (3).
‡Charité, Charité University Hospital, Berlin, Germany; NRC, National Reference Center for Mycobacteria, Borstel, Germany. 
§Ȥ
2 test, software package Stata version 9 (Stata Corporation, College Station, TX, USA). 
Figure. Denaturating high-performance liquid 
chromatography proﬁ   les after separation of 
PCR-ampliﬁ   ed internal transcribed spacer 
regions of Mycobacterium spp. Strain 
designations from above: DSMZ 43223, M. 
intracellulare, sequevar MIN-A type strain; 
MM 1675, M. intracellulare, sequevar MIN-A, 
patient strain; DSMZ 44623, M. chimaera sp. 
nov., sequevar MAC-A type strain; MM 119; M. 
chimaera sp. nov., sequevar MAC-A, patient 
strain; MM 300, M. intracellulare, sequevar 
MIN-C, patient strain.Mycobacterium chimaera sp. nov.
because of the low number of cases analyzed (12 patients) 
(2). The most striking result of our study was that all 3 M. 
intracellulare, sequevar Min-A, isolates were unequivocal-
ly associated with severe mycobacterial lung disease. De-
spite the low case numbers, these ﬁ  ndings suggest that this 
species is more virulent and justify further epidemiologic 
investigations to verify this observation.
In agreement with other authors, our observations in-
dicate that a precise differentiation of MAC isolates may 
provide clinically relevant data (4,5). This conclusion is in 
accord with a recently published review that discusses ad-
vances and future aspects of MAC genomics and points out 
the importance of taking into account the heterogeneity of 
MAC species (15).
If one assumes substantial differences in pathogenic-
ity, the allocation of MAC isolates to deﬁ  ned species may 
facilitate diagnosis of mycobacterial lung disease. How-
ever, implementation of a staged identiﬁ  cation procedure 
in routine microbiologic laboratories requires the availabil-
ity of commercial, easy-to-use test kits. Because diagnosis 
of NTM infections remains a challenge and often results 
in indecisive situations that prolong the administration of 
adequate therapy, the rapid identiﬁ  cation of MAC-related 
species highly predictive for mycobacterial disease would 
be very useful. 
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